ESPE Abstracts (2022) 95 P1-380

ESPE2022 Poster Category 1 Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology (56 abstracts)

Effect of Long Acting Gonadotropin Releasing Hormone Agonists on Height Outcome in Children

Shaimaa Sahmoud 1 , Sanjay Gupta 2 & Sandra Greetham 3

1Paediatric Post Graduate Doctor In Training, Hull University Hospital, Hull, United Kingdom; 2Consultant Paediatrician (Diabetes and Endocrinology), Hull University Hospital, Hull, United Kingdom; 3Children's Endocrine Nurse, Hull University Teaching Hospital, Hull, United Kingdom

Gonadotropin releasing hormone agonists (GnRHa) stops premature sexual maturation in young children and preserve the potential of achieving acceptable adult height.

Aim: To assess the efficacy of long acting GnRHa in suppressing early pubertal development and its impact on height outcome in our patient population.

Methods: Records of children treated with GnRHa since 2018 at Hull University Hospital; UK were reviewed. Predicted adult height was calculated using the GrowthXP Endo electronic toolkit.

Results: GnRHa were given to 18 children, 12(67%) for precocious puberty (Group A), and 6(33%) in an attempt to optimise target adult height potential. All children were females. Mean age (years) at start of treatment was 7.6 ±1.2, and 9.8 ±0.75 for group A and B respectively. Group A duration of treatment (years) was 1.8±0.79 compared to 1.37±0.87 in group B. Within group A, mean difference between bone and actual age was 1.4±0.8 years. In both groups, 11 (61%) of the children had initial low dose 11.25mg Triptorelin injection followed by 22.5 mg dose, while 39% started on the 22.5 mg dose. Before and after treatment height difference (cm) was 131.8±2.9 Vs 139.2±10.7 (P< 0.001) in group A and 132.6±3.2 Vs 137.5±4.7 (P<0.001) group B. Predicted adult height Difference (cm) was 170.8±2.5 Vs 171.4±8 in group A (P<0.001) and 157.6±4.7 Vs 158.7±5.2 (P<0.001) in group B. Predicted adult height (cm) was higher at the end of treatment (161.2±7.7 Vs 160.7±7.1 P=0.001). The treatment was universally tolerated well by our patients.

Conclusion: When commenced before 10 years of age, long acting GnRHa treatment increased potential height growth for girls treated for precocious puberty in our population.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.